遺伝子クローニングサービスの世界市場：市場規模・シェア分析 (サービス別・用途別・遺伝子の種類別・エンドユーザー別)、産業の需要予測 (～2030年)

市場概要

世界の遺伝子クローニングサービスの市場規模は、2023年に31億5,410万米ドルと推計され、2024年から2030年までに18.1%のCAGRで成長し、2030年には100億1,960万米ドルに達すると予測されています。

慢性疾患の増加、正確な医薬品へのニーズの高まり、遺伝性疾患の大幅な発生が業界の発展に寄与すると予測されます。さらに、政府による支出の増加、バイオテクノロジー分野の研究開発、遺伝学の技術向上により、医薬品分野の研究が大幅に急増し、今後数年間で業界の収益を押し上げると予測されています。

主要な洞察

2023年、遺伝子合成カテゴリーは45%の業界シェアを占めています。その普及は、多数の垂直分野での広範な応用と世界の研究活動の成長に起因します。

2023年、遺伝子治療は業界シェア35%を占めています。その成長可能性は、以前は救いようのなかった病気や疾患を治療する能力にあります。

2023年現在、北米地域が約55%の業界最大シェアを占めていますが、これはバイオテクノロジーおよび製薬産業における研究開発が盛んなためです。

当レポートでは、世界の遺伝子クローニングサービスの市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、サービス別・用途別・遺伝子の種類別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：サービス別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：遺伝子の種類別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：サービス別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：遺伝子の種類別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：サービス別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：遺伝子の種類別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Genscript Biotech Corporation
• Eurofins Scientific SE
• Charles River Laboratories International Inc.
• Takara Bio Inc.
• Creative Biogene
• Synbio Technologies
• Aragen Life Sciences Ltd.
• Sino Biological Inc.
• Curia Global Inc.

第31章 付録

Market Overview

The market value of global gene cloning services is estimated to be USD 3,154.1 million in 2023 and is projected to reach USD 10,019.6 million by 2030, with a Compound Annual Growth Rate (CAGR) of 18.1% during the period from 2024 to 2030.

The rising occurrence of chronic illnesses, the growing need for accurate drugs, and the substantial occurrence of inherited conditions are projected to contribute to the development of the industry. Moreover, the substantial surge in research in the medicinal field because of the rise in spending by governments, the development of the biotechnological sector, and technical improvements in genetics are projected to propel the industry revenue in the coming years.

Nowadays we see a growing trend of a sedentary way of life, which goes with alcohol consumption, increased smoking, terminal fast food, and exercise too rare. The adoption of this unhealthy diet is causing the state of health of people to be even more unhealthy and also the development of many long-term diseases.

Diseases make things worse and serious diseases will be the things that can even end the life of a person. This therefore led to an increase in the need for such methods of treatments that are either more efficient or more effective in curing the disease.

Key Insights

In 2023, the gene synthesis category grips the dominating industry share of 45%.

Its acceptance stems from its extensive application in numerous verticals and the growing research activities globally.

Researchers are progressively using gene synthesis along with techs such as CRISPR genome editing and synthetic biology for enhanced solutions in life sciences.

Gene synthesis can be used in the fields of neurosciences, therapeutic antibody structure development, plant biology, cancer biology, genetics, and biochemistry.

Initially, it is considered a tool pushed to the front for economical tasks of the traditional cloning and molecular biology method that sometimes need time and are expensive.

In 2023, gene therapy grips a leading industry share of 35%.

Its potential lies in its capability to cure previously irredeemable ailments or diseases.

More than 50,000 inherited illnesses caused by gene mutations have been recognized, making gene treatment a promising method.

Understanding protein pathways and gene expression allows for the testing and effectiveness of more therapies.

In 2023, the North American region holds the largest industry share of approximately 55% because of substantial R&D in the biotechnology and pharmaceutical industries.

Reasons contributing to this comprise the high occurrence of chronic illnesses, a strong healthcare system, and acceptance of enhanced technologies.

Top biotechnology businesses and genomic research projects with significant investments are propelling industry development.

Positive perceptions of health and genetic testing to individuals may stimulate research of genomics in medicine to evaluate therapeutic purposes.

Due to the well-established healthcare, general public knowledge, and individual capacity of a modern person to cover the expenses related to treatment, and along with the implementation of gene therapies for cancer, Canada provides the largest market share in North America.

Enhanced healthcare coverage as well as steady improvement of pharmaceutical and biotech industries is going to result in a substantial portion in the forecast. Additionally, rising chronic diseases, and growing gene cloning in diagnostic and drug development, will support Europe in ranking within the top five markets.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by service
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by gene type
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Service (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by Gene Type (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Service (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by Gene Type (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Service (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by Gene Type (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Service (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by Gene Type (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Service (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by Gene Type (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Service (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by Gene Type (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Service (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by Gene Type (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Service (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by Gene Type (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Service (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by Gene Type (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Service (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by Gene Type (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Service (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by Gene Type (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Service (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by Gene Type (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Service (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by Gene Type (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Service (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by Gene Type (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Service (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by Gene Type (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Service (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by Gene Type (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Service (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by Gene Type (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Service (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by Gene Type (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Service (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by Gene Type (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Service (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by Gene Type (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Service (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by Gene Type (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Service (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by Gene Type (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Service (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by Gene Type (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Thermo Fisher Scientific Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Genscript Biotech Corporation
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Eurofins Scientific SE
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Charles River Laboratories International Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Takara Bio Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Creative Biogene
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Synbio Technologies
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Aragen Life Sciences Ltd.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Sino Biological Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Curia Global Inc.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports